Heart Failure Society of America 13th Annual Scientific Meeting to Focus on a Bench-To-Bedside Approach September 13-16, 2009, Hynes Convention Center, Boston, MA National and International Health Care Professionals Will Convene to Learn, Discuss and Debate New Research Findings and Treatment Strategies for Heart Failure Patients
BOSTON, Sept. 14 /PRNewswire/ -- The Heart Failure Society of America's (HFSA) 13th Annual Scientific Meeting convened Sunday, September 13, 2009 at the Hynes Convention Center in Boston. This three-day meeting -- a forum for heart failure specialists to present research findings and advances in treatment -- will address emerging trends in research and new developments in the approach to treating patients with this condition.
The scientific program will kick off with an opening plenary session, "Personalized Medicine: The Dawn of a New Era," today at 8:30 a.m. This session will be anchored by Journalist David Duncan, author of The Experimental Man: What one man's body reveals about his future, your health, and our toxic world.
Following the Opening Plenary will be simultaneous sessions with presentations by national and international heart failure experts, scientists, and allied health care professionals. Many will focus on the progressive treatments for heart failure and the increased risk faced by patients.
"This year's conference will present exciting new information," said Dr. Douglas Mann, President, HFSA. "Leaders in the field will discuss causes and treatment of heart failure and the important socio-economic issues surrounding this condition."
Other scientific meeting sessions that address important heart failure issues include:
-- Clinical Use of Stem Cells in the Heart: What Have We Learned?
-- Cardiovascular Disease: The Hidden Killer in Adult Survivors of
Childhood Cancer
-- Is the Physical Exam Obsolete?
-- New Development in Gene Therapy for Heart Failure
Late Breaking heart failure Clinical Trials to be presented include:
-- Improving Evidence-Based Care for Heart Failure in Outpatient Cardiology
Practices: Primary Results of IMPROVE HF
-- Reduction in the Risk of Heart Failure with Preventive Cardiac
Resynchronization Therapy: MADIT-CRT
-- Effects of Rolofylline, A Selective Adenosine A1 Antagonist in Patients
Hospitalized for ADHF and Renal Impairment: Findings from the PROTECT
study
For a complete list of annual meeting sessions or for details on attending the conference, call (617) 226-7183 or visit www.hfsa.org and click on Annual Scientific Meeting. There is no registration fee for accredited journalists. Interview areas will be available on-site in addition to a fully-staffed press room with phone and internet accessibility. You may also follow news from the 2009 annual meeting on Twitter #hfsa.
About Heart Failure
Heart failure is a progressive condition in which the heart muscle becomes weakened after it is injured from heart attack or high blood pressure and gradually loses its ability to pump enough blood to supply the body's needs. Many people are not aware they have heart failure because the symptoms are often mistaken for signs of getting older. Heart failure affects from 4.6 to 4.8 million individuals in the United States. Demographic and clinical evidence strongly suggest the prevalence of heart failure will increase throughout the next decade. Ten to 15 years ago heart failure was considered a "death sentence;" however, recent advances in treatment have shown that early diagnosis and proper care in early stages of the condition are key to slowing, stopping or in some cases reversing progression, improving quality of life, and extending life expectancy. For more information on heart failure, please visit www.abouthf.org.
About the Heart Failure Society of America
The Heart Failure Society of America (HFSA) is a nonprofit educational organization, founded in 1994 as the first organized association of heart failure experts. Today HFSA has over 1,700 members and provides a forum for all those interested in heart function, heart failure research and patient care. The Society also serves as a resource for governmental agencies (FDA, NIH, NHLBI, CMS). The HFSA Annual Scientific Meeting is designed to highlight recent advances in the development of strategies to address the complex epidemiological, clinical and therapeutic issues of heart failure. Additional information on HFSA can be found at www.hfsa.org.
SOURCE The Heart Failure Society of America
The Heart Failure Society of America
CONTACT: Ben Hendricks for The Heart Failure Society of America,+1-617-226-7183, or Cell, +1-522-2978, bhendricks@bellpottingerusa.com
Web site: http://www.hfsa.org/